Suggested remit: To appraise the clinical and cost effectiveness of abrocitinib within its marketing authorisation for moderate to severe atopic dermatitis in people aged 12 and over.
- Status:
- Discontinued
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 3768
Project Team
- Project lead
- Shonagh D'Sylva
Email enquiries
If you have any queries please email TAteam2@nice.org.uk
Stakeholders
- Companies sponsors
- Pfizer (abrocitinib)
- Others
- Department of Health and Social Care
- NHS England
- NHS Barking & Dagenham CCG
- NHS Walsall CCG
- Welsh Government
- Patient carer groups
- Action for Sick Children
- Allergy UK
- British Skin Foundation
- Changing Faces
- Contact
- Eczema Outreach Support
- Let’s Face It
- National Eczema Society
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Professional groups
- Association of Paediatric Emergency Medicines
- British Association for Immediate Care
- British Association of Dermatologists
- British Dermatological Nursing Group
- British Society for Cutaneous Allergy
- British Trauma Society
- Neonatal and Paediatric Pharmacists Group
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Paediatrics & Child Health
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Primary Care Dermatology Society
- UK Clinical Pharmacy Association
- Associated public health groups
- Public Health England
- Public Health Wales
- Comparator companies
- Accord Healthcare (azathioprine, methotrexate, mycophenolate mofetil)
- ADVANZ Pharma (methotrexate)
- Aspen (azathioprine)
- Cipla (methotrexate)
- Dexcel Pharma (ciclosporin)
- Eli Lilly (baricitinib)
- Ennogen Pharma (alitretinoin, azathioprine)
- Hospira UK (methotrexate)
- medac GmbH (methotrexate)
- Morningside Healthcare (methotrexate)
- Mylan (azathioprine, ciclosporin)
- Nordic Pharma (methotrexate)
- Novartis Pharmaceuticals (ciclosporin)
- Orion Pharma (methotrexate)
- Pfizer (methotrexate)
- Roche (mycophenolate mofetil)
- Rosemont Pharmaceuticals (methotrexate)
- Sandoz (methotrexate)
- Sanofi Genzyme (dupilumab)
- Santen UK (ciclosporin)
- Stiefel (alitretinoin)
- Teva Pharma (mycophenolate mofetil)
- Therakind (methotrexate)
- Tillomed Laboratories (azathioprine, mycophenolate mofetil)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Alliance
- NHS Confederation
- Scottish Medicines Consortium
- Welsh Health Specialised Services Committee
- Relevant research groups
- British Epidermo-Epidemiology Society
- Centre of Evidence-based Dermatology, University of Nottingham
- Cochrane Skin Group
- Genomics England
- MRC Clinical Trials Unit
- National Institute for Health Research
- Skin Treatment & Research Trust
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 August 2021 | Due to significant capacity challenges NICE has paused the development of the Single Technology Appraisals for [ID3768] abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over, [ID3733] Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over and [ID3734] Tralokinumab for treating moderate to severe atopic dermatitis. All 3 topics will be appraised together as a Multiple Technology Appraisal under [ID3960]. |
| 05 August 2021 | Discontinued |
| 21 July 2021 | We are continuing to face significant capacity challenges and will be delaying the development of abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]. This topic will now be considered as part of a multiple technology appraisal. We anticipate that it will be considered by the technology appraisal committee in early 2022. |
| 21 July 2021 | Schedule affected by COVID-19. We are continuing to face significant capacity challenges and will be delaying the development of abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]. This topic will now be considered as part of a multiple technology appraisal. We anticipate that it will be considered by the technology appraisal committee in early 2022. |
| 15 March 2021 | Invitation to participate |
| 25 November 2020 - 23 December 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual